A 12-year surveillance study on distribution and antimicrobial resistance of gram-positive bacteria in Iran

伊朗革兰氏阳性菌分布及抗菌素耐药性12年监测研究

阅读:1

Abstract

Strengthening knowledge through surveillance and research is one of the main steps in treating antibiotic-resistant infections. The present study was therefore designed to analyse long-term antimicrobial resistance trends over the 12 years in Iran. Data from the patient's clinical specimens were collected over 12 years from January 2012 until December 2023. Antimicrobial susceptibility patterns of gram-positive bacteria (GPB) were identified using the Kirby-Bauer disk diffusion method (DDM) and resistance proportions to most commonly used antibiotics were calculated for each GPB. All data were analysed using descriptive statistics. A total of 30,548 cultures were positive for GPB. Staphylococcus aureus (S. aureus) with 59.5% and coagulase-negative staphylococci (CoNS) with 26.6% frequently isolated from blood specimens. S. aureus was the frequently isolated organism in ≥ 6 years of age groups. S. aureus isolates showed the highest and lowest resistance rates to penicillin (91.8%) and vancomycin (1.1%), respectively. Nitrofurantoin (10.5%) was the most effective antimicrobial agent on Enterococcus spp. Time trends in antibiotic resistance revealed a sharp increase for several antibiotics: from 33.9% in 2013 to 54.5% in 2023 for gentamicin; from 51.2% in 2013 to 76.4% in 2023 for ceftriaxone; from 34.5% in 2013 to 54.8% in 2023 for imipenem; and from 66.7% in 2012 to 81.8% in 2023 for cefixime. The present research suggests that vancomycin and nitrofurantoin are effective antibiotics against infections caused by Staphylococcus and Enterococcus spp., respectively. This data revealed that the continuous monitoring of antimicrobial resistance (AMR) patterns is necessary for selecting the suitable drug.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。